FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

KPV

Lys-Pro-Val / KPV Tripeptide

Recovery & Repair

KPV is a naturally occurring anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically representing residues 11-13 of the full hormone sequence. Despite lacking the melanocortin receptor binding core of alpha-MSH, KPV retains potent anti-inflammatory activity through direct NF-kB inhibition and has shown particular promise in inflammatory bowel disease and mucosal inflammation research. It represents a rare example of a minimal bioactive peptide fragment that maintains therapeutic activity without the parent molecule's hormonal effects.

작용 메커니즘

C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Potent anti-inflammatory that inhibits NF-kB translocation to the nucleus, reducing TNF-alpha, IL-6, and IL-1 beta production. Crosses the blood-brain barrier.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 200-500mcg daily via subcutaneous injection or oral capsule. For gut inflammation, oral or rectal administration studied at 100-400mcg. Cycles of 4-8 weeks.

연구 노트

Clinical Research Status

KPV has not entered formal clinical trials as a standalone therapeutic but is under active preclinical investigation for inflammatory bowel disease, colitis, and dermatological conditions. Research groups at Tulane University and the University of Colorado have published extensively on its anti-inflammatory mechanisms in colonic tissue. The peptide is being explored in nanoparticle delivery systems for targeted oral delivery to inflamed intestinal mucosa. Its status remains investigational with no regulatory approvals in any jurisdiction.

Key Published Findings

A 2003 study in the Journal of Biological Chemistry demonstrated KPV enters cells and translocates to the nucleus where it directly inhibits NF-kB activation and subsequent pro-inflammatory cytokine transcription (IL-1beta, IL-6, TNF-alpha). Research published in Inflammatory Bowel Diseases showed KPV significantly reduced colonic inflammation in DSS-induced colitis models, with efficacy via both systemic injection and oral administration. Antimicrobial studies demonstrated activity against Staphylococcus aureus and Candida albicans through mechanisms independent of its anti-inflammatory pathway. A 2020 nanoparticle study showed orally-delivered KPV in hyaluronic acid-functionalized nanoparticles specifically accumulated in inflamed colonic tissue.

Safety Profile

KPV has demonstrated an excellent safety profile in all available preclinical studies with no observed toxicity at doses far exceeding therapeutic concentrations. Unlike full-length alpha-MSH, KPV has minimal melanotropic activity and does not cause skin pigmentation changes, sexual arousal, or other melanocortin-mediated effects. The tripeptide is rapidly metabolized by standard aminopeptidases, reducing risk of systemic accumulation. No adverse effects have been reported in community use, though formal human safety studies with defined endpoints have not been published.

Drug Interactions & Contraindications

No formal drug interaction studies exist, though KPV's NF-kB inhibition could theoretically potentiate other anti-inflammatory or immunosuppressive agents (TNF-alpha inhibitors, corticosteroids). Patients on biologic immunosuppressants for IBD (infliximab, adalimumab) should exercise caution with concurrent KPV due to potentially additive immunosuppression. Its antimicrobial properties suggest it should not interfere with antibiotic therapy and may provide synergistic benefit. No absolute contraindications have been identified in published literature.

Comparison to Related Compounds

Unlike its parent molecule alpha-MSH, KPV does not bind melanocortin receptors and produces no tanning, appetite suppression, or sexual side effects, isolating only the anti-inflammatory activity. Compared to BPC-157 (another gut-protective peptide), KPV works through a distinct mechanism (NF-kB inhibition vs. nitric oxide pathway modulation) and is more specifically anti-inflammatory rather than broadly tissue-protective. Relative to mesalamine (5-ASA) used in IBD, KPV acts upstream at the NF-kB level rather than downstream at the prostaglandin level. Its minimal size (3 amino acids) makes it exceptionally stable and inexpensive to synthesize compared to larger therapeutic peptides.

Community Observations

Users most commonly employ KPV for gut inflammation, often administered orally in capsule form (200-500 mcg) or subcutaneously (200-400 mcg) for systemic anti-inflammatory effects. Reports suggest noticeable improvement in IBS and IBD symptoms within 1-2 weeks of consistent use, particularly regarding abdominal pain and stool consistency. It is frequently combined with BPC-157 in gut-healing protocols, with users reporting synergistic benefits from the complementary mechanisms. Some practitioners recommend it for post-infectious gut inflammation and as part of mold/biotoxin illness recovery protocols.

반감기

~30 minutes

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 12 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

Lys-Pro-ValKPV Tripeptide

자주 묻는 질문

KPV란 무엇인가요?

KPV is a naturally occurring anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically representing residues 11-13 of the full hormone sequence. Despite lacking the melanocortin receptor binding core of alpha-MSH, KPV retains potent anti-inflammatory activity through direct NF-kB inhibition and has shown particular promise in inflammatory bowel disease and mucosal inflammation research. It represents a rare example of a minimal bioactive peptide fragment that maintains therapeutic activity without the parent molecule's hormonal effects.

KPV는 어떻게 작용하나요?

C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Potent anti-inflammatory that inhibits NF-kB translocation to the nucleus, reducing TNF-alpha, IL-6, and IL-1 beta production. Crosses the blood-brain barrier.

KPV의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

KPV의 반감기는 얼마인가요?

~30 minutes

KPV의 다른 이름은 무엇인가요?

Lys-Pro-Val, KPV Tripeptide

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기